Study of Cannabidiol (CBD) in Healthy Volunteers

Status Completed

Clinical Trial Summary

This was a prospective, single-centre, open label, randomized, two-arm, parallel design study to evaluate the effect of four-weeks consumption of active study product on primary endpoint in healthy adults

Clinical Trial Description

Cannabidiol (CBD), a non-psychoactive component of Cannabis sativa L., has been purported to have a variety of beneficial physiological effects including but not limited to, pain relief, anti-anxiety, anti-seizure, anti-depressant, anti-oxidant, and anti-inflammatory. Despite the enthusiasm of the CBD industry for these claims, the empirical evidence supporting favourable physiological responses is inconsistent. These discrepancies may in part be explained by differences in CBD bioavailability when administered orally that in turn may be influenced by non-standardized CBD formulation, and/or the body size and composition of the recipient. The purpose of this study was to test the bioavailability of two doses of a novel CBD formation given twice per day for three consecutive days in healthy study subjects and explore their potential acute anti-inflammatory properties as assessed by highly sensitive immunologic assays. The rationale for conducting the study was to evaluate the pharmacokinetic (PK) profile of a novel formulation of CBD designed to improve bioavailability given at two dose levels twice per day for three consecutive days. Although previous studies conducted in healthy study subjects have documented the safety and PK profile for a single dose of the test product, multiple ascending dose studies have not yet been conducted. In addition to evaluating multiple ascending dose PK, the pharmacodynamic properties of the CBD were assessed using ex vivo lipopolysaccharides (LPS) stimulated whole blood assays and high sensitivity serum cytokine assays. ;

Study Design

Related Conditions & MeSH terms

Immune System and Related Disorders
Immune System Diseases

Clinical Trial Details

NCT number	NCT06286839
Study type	Interventional
Source	NextEvo Inc.
Contact
Status	Completed
Phase	N/A
Start date	May 12, 2022
Completion date	December 14, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03663933` - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation	Phase 2
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Recruiting	`NCT04339777` - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity	Phase 2
Not yet recruiting	`NCT05969821` - Clonal Hematopoiesis of Immunological Significance
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT02527187` - Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa	Phase 2
Completed	`NCT01441076` - Anakinra for Behcet s Disease	Phase 1/Phase 2
Completed	`NCT01472263` - Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases	Phase 3
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Suspended	`NCT04642066` - Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters	N/A
Completed	`NCT02294552` - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT	Phase 2
Completed	`NCT01727973` - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy	Phase 1/Phase 2
Completed	`NCT04103099` - Impact of HLNatural Immune Supplement on Colds	N/A
Recruiting	`NCT03344094` - Mechanism of Action of Ocrelizumab in Multiple Sclerosis	N/A
Active, not recruiting	`NCT05445284` - Group Education Trial to Improve Transition for Parents of Adolescents With T1D	N/A
Recruiting	`NCT06104111` - Epigenetic Memory of Vitamin D Supplementation	Phase 1
Not yet recruiting	`NCT05616117` - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Completed	`NCT01510626` - Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center	Phase 1
Completed	`NCT01490177` - Single Center Food Allergy Oral Immunotherapy Study	Phase 1
Completed	`NCT03922087` - No-worry Baby Project